Trending News Today: GOP Right to Try Bill Under Fire from Top Democrat

A revised version of the “right to try” bill faces scrutiny from the top Democrat from the House Energy and Commerce Committee, according to The Hill. Rep Frank Pallone Jr (D-NJ), ranking member of the committee, said that the GOP bill may put patients at risk by removing FDA involvement in access to experimental drugs. Pallone said that the parties should work together to develop a bipartisan consensus that would protect patients and ensure access to investigational treatments while upholding the approval process, according to the article.

Yesterday, a bipartisan group of senators introduced legislation that would bolster the DEA’s ability to combat opioid abuse, The Hill reported. The new bill would authorize the DEA to consider rates of overdose death and abuse when setting limits for the production of Schedule 1 and 2 controlled substances, according to the article. Currently, the DEA is only allowed to consider past sales and demand for the products.

A recent study found that the Great Recession—starting in 2007—resulted in a significant number of patients not adhering to their blood pressure and diabetes medications, according to STAT. Nonadherence and other factors resulted in less control of blood pressure and blood glucose measures after the recession hit compared with other time periods, STAT reported. These findings provide strong evidence that economic issues play a role in public health, according to the article.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Study suggests that covering high-value medications benefits patients at no extra cost to insurers.
Early initiation of combination targeted therapy to address multiple sites of pathophysiology (the physiologic approach) might slow T2D progression and improve patient outcomes. Complementary mechanism of actions and weight and glycemic effects of basal insulin and GLP-1 RAs support this combination. New fixed dose basal insulin and GLP-1 RA combination products could facilitate the application of the physiologic approach, reduce injection burden, and increase medication adherence. Pharmacists should be aware of appropriate candidates for insulin and GLP-1 RA combination therapy and how to effectively counsel patients starting on these therapies. This activity will provide key strategies and case scenarios to optimize patient education and management of diabetes with the GLP-1 RA/ basal insulin combination.
Pharmacy Times Continuing Education™ has built three (3) CE accredited, detailed simulation-based, branching patient cases (for a total of 2 CE credits) that match the patient population, medical conditions and situations encountered in patients with diabetes that are on fixed-dose combination therapy. Participants are given multiple ways to progress through the simulation and, based on the learners’ choices, the simulation evolves, decision by decision. This simulation provides an approach for teaching clinical reasoning because the learner makes decisions that impact the outcome of his or her patient. The activity will be accredited for a total 2.0 credits after completing all 3 cases.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.